Vienna, Austria

ESTRO 2023

Session Item

Sunday
May 14
16:45 - 17:45
Plenary Hall
Lung
Caroline Maguire, United Kingdom;
Sara Ramella, Italy
Proffered Papers
Clinical
16:55 - 17:05
Do patients with lung cancer and a genetic risk for rheumatoid arthritis have increased toxicity?
Alan McWilliam, United Kingdom
OC-0608

Abstract

Do patients with lung cancer and a genetic risk for rheumatoid arthritis have increased toxicity?
Authors:

Alan McWilliam1, Sarah Kerns2, Deborah Marshall3, David Azria4, Jenny Chang-Claude5, Ananya Choudhury1, Sara Gutiérrez-Enríquez6, Maarten Lambrecht7, Tiziana Rancati8, Dirk De Ruysscher9, Petra Seibold10, Chris Talbot11, Ana Vega12, Liv Veldeman13, Adam Webb14, Kathryn Banfill1, Corinne Faivre-Finn1, Barry Rosenstein15, Catharine West16

1The University of Manchester, Division of Cancer Science, Manchester, United Kingdom; 2Medical College of Wisconsin, Radiation Oncology, Wisconsin, USA; 3Mount Sinai, Icahn School of Medicine , New York, USA; 4University Montpellier, Federation Universitaire d’oncologie radiothérapie d’Occitanie Méditerranée, Montpellier, France; 5German Cancer Research Centre, Division of Cancer Epidemiology, Heidelburg, Germany; 6Vall d’Hebron Barcelona Hospital Campus, Hereditary Cancer Genetics Group, Barcelona, Spain; 7Leuvens Kanker Instituut, Department of Radiotherapy-oncology, Leuven, Belgium; 8Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milian, Italy; 9Maastricht University Medical Center, Department of Radiation Oncology, Maastricht, The Netherlands; 10Germant Cancer Research Centre, Division of Cancer Epidemiology, Heidelburg, Germany; 11University of Leicester, Leicester Cancer Research Centre, Leicester, United Kingdom; 12Grupo de Medicina Xenómica, Fundación Pública Galega de Medicina Xenómica,, Santiago de Compostela, Spain; 13Ghent University Hospital and Ghent University, Department of Radiation Oncology, Ghent, Belgium; 14University of Leicester, Department of Genetics and Genome Biology, Leicester, United Kingdom; 15Department of Radiation Oncology Mount Sinai, Department of Genetics and Genomic Sciences, New York, USA; 16The University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom

Show Affiliations
Purpose or Objective

Overlapping genes are involved with rheumatoid arthritis (RA) and DNA repair pathways. Therefore, we hypothesised that patients with a high polygenic risk score (PRS) for RA will have an increased risk of radiotherapy (RT) toxicity.

Material and Methods

Data from 530 patients with lung cancer were available from the multicentre prospective REQUITE study. Germline DNA was genotyped using Illumina OncoArray-500K BeadChips and imputed using the 1000 Genomes Project Phase 3. PRS and weighted-PRS (wPRS) were calculated for RA (101 SNPs) and analysed as continuous variables and using a >90th percentile cut-off. Univariable and multivariable linear regression models analysed relationships with: 1) acute and late standardised total averaged toxicity (STAT) scores; and 2) individual toxicity end points. Acute toxicity was defined as max reported toxicity within 90 days of RT and late toxicity defined as max reported after 90 days for cough, dyspnoea, pneumonitis, dysphagia, and oesophagitis.  Multivariable analyses included the following pre-selected adjustment variables: gender, age, smoking history, chemotherapy, forced expiratory volume (FEV), lung v20, oesophagus v35, prescription dose (biologically equivalent dose), and diagnosis of chronic obstructive pulmonary disease (COPD).

Results

No significant association was found between PRS or wPRS with acute or late STAT. Smoking history, (p=0.03), lung v20 (p=0.008), oesophagus v35 (p=0.02) and COPD (p=0.01) showed a significant association with STAT acute. Lung v20 (p=0.03), oesophagus v35 (p=0.01) and COPD (p < 0.01) were associated with STAT late. Patients with >90th percentile for PRS showed a beta coefficient of 0.17, p=0.06 associated with worse late STAT. Patients >90th percentile for wPRS showed no association with worse STAT late.

Analysing individual toxicity end points identified that patients >90th percentile for wPRS experienced significantly worse acute (coefficient 0.18, p=0.05) and late (coefficient 0.2, p = 0.03) oesophagitis. Smoking history (p=0.01), FEV (p=0.02) and COPD (p=0.05) increased risk of acute oesophagitis. FEV (p=0.02) and higher oesophagus v35 (p=0.03) were also significantly associated with worse late oesophagitis, table 2.


Conclusion

Patients with lung cancer who have a high genetic load for RA have an increased risk of acute and late oesophagitis. Results need to be further validated but suggest an actionable target for preferential oesophagus sparing in these patients.